Do men undergoing male-to-female hormone therapy (estrogen and anti‑androgen treatment) commonly experience mood swings, particularly during the first 3–6 months of therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mood Swings in Male-to-Female Hormone Therapy

Current evidence indicates that trans women undergoing feminizing hormone therapy (estrogen and anti-androgens) do experience mood swings, particularly during the first 3-6 months of treatment, but these changes are generally associated with overall improvements in mental health rather than adverse psychiatric outcomes. 1

Expected Emotional Changes During Early Treatment

The Endocrine Society Clinical Practice Guidelines document the timeline of feminizing effects in male-to-female transition 2. While mood swings are not explicitly listed in the standardized physical effects table, prospective research directly addressing subjective symptoms provides clear evidence:

  • Mood swings and emotional instability increase persistently during the first 12 months of feminizing hormone therapy 1
  • These changes typically begin within the first 3-6 months of treatment initiation
  • The pattern represents a shift toward affect variability profiles more consistent with cisgender women 3

The Paradox: Mood Changes vs. Mental Health Improvement

Critically, while mood swings do occur, they should not be conflated with psychiatric deterioration. The most recent systematic review evidence demonstrates:

  • No evidence that gender-affirming hormone therapy has adverse mental health outcomes 4
  • Depression decreases by approximately 20% after 1 year of treatment in both trans women and trans men 4
  • Quality of life improves by 16% in trans women after 1 year 4
  • Overall psychoneurotic distress decreases most prominently after hormone therapy initiation 5

Clinical Context and Counseling Points

What to Tell Patients:

Trans women should expect increased emotional variability, including:

  • Mood swings (persistent throughout first year) 1
  • Emotional instability (persistent throughout first year) 1
  • Breast tenderness (persistent) 1
  • Hot flashes and night sweats (persistent) 1

Important Distinction:

The 2025 study on affect variability clarifies that variability in low mood increased after 3 and 12 months in the feminizing hormone group 3. This represents fluctuation patterns rather than sustained negative mood states. The increased variability reflects a normalization toward cisgender female patterns of emotional experience.

Monitoring Recommendations:

While the 2009 Endocrine Society guidelines mention monitoring for "adverse psychological changes" in trans men on testosterone 2, they do not specifically flag mood swings as a concerning adverse event requiring intervention in trans women. The guidelines emphasize:

  • Regular psychological monitoring during endocrine transition
  • Pretreatment counseling about all expected effects
  • Recognition that these changes occur within a context of overall mental health improvement

Critical Caveat About Testosterone Studies

Disregard evidence from 6 regarding testosterone and depression in cisgender men—this is not applicable to trans women receiving feminizing therapy. Trans women receive estrogen and anti-androgens, not testosterone, making this study irrelevant to the question at hand.

Bottom Line for Clinical Practice

Counsel trans women that mood swings are a common, expected effect of feminizing hormone therapy that typically emerges in the first 3-6 months and may persist throughout the first year. 1 However, reassure them that:

  • This does not represent psychiatric deterioration
  • Overall mental health typically improves significantly
  • These changes reflect a shift toward typical female hormonal patterns
  • The benefits in terms of quality of life and reduced gender dysphoria substantially outweigh these transient emotional adjustments 4

The occurrence of mood swings should not be considered a reason to discontinue or avoid hormone therapy, as the overall trajectory is toward improved psychological well-being.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.